Report summarizes cancer therapy study findings from University Autonoma of Barcelona
2007 NOV 19 -- Fresh data on cancer are presented in the report 'FANCD2 depletion sensitizes cancer cells repopulation ability in vitro.' "Inactivation of Fanconi anemia/BRCA pathway in some cancers causes increased sensitivity to various drugs used for chemo-therapy. Several approaches have been suggested to artificially disrupt this pathway for better treatment," scientists in Barcelona, Spain report. "In our study, we have utilized RNA interference technique to knock-down the expression of FANCD2 and sensitize cancer cells undergoing treatment with DNA damaging agents. For this purpose, we transiently depleted FANCD2 by siRNA in a number of breast, bladder, or liver cancer cell lines and screened for mitomycin C or gamma-irradiation sensitivity changes. We could show that knocking-down FANCD2 gene expression increases sensitivity of cancer cells to mitomycin C and to less extent to gamma-rays. Importantly, this effect strongly correlates to repopulation ability of cancer cells and those cell lines with significant FANCD2 depletion revealed decreased recurrence capacity," wrote A. Lyakhovich and colleagues, University Autonoma of Barcelona. The researchers concluded: "In summary, the results we presented show proof of principle that opens new possibilities for further preclinical trials." Lyakhovich and colleagues published their study in Cancer Letters (FANCD2 depletion sensitizes cancer cells repopulation ability in vitro. Cancer Letters, 2007;256(2):186-95). For more information, contact A. Lyakhovich, Group of Mutagenesis, Dept. of Genetics and Microbiology, Universitat Autonoma de Barcelona, 08193 Bellaterra, Barcelona, Spain. Publisher contact information for the journal Cancer Letters is: Elsevier Science Ireland Ltd., Customer Relations Manager, Bay 15, Shannon Industrial Estate, Co. Clare, Ireland. Keywords: Spain, Barcelona, Cancer Therapy, Cancer, Oncology, Therapy, Treatment. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2007, Biotech Business Week via NewsRx.com.
|
